2,3,4,6-O-四特戊酰基-ALPHA-D-溴代吡喃葡萄糖

2,3,4,6-O-四特戊酰基-ALPHA-D-溴代吡喃葡萄糖性质、用途与生产工艺

简介

2,3,4,6-O-四特戊酰基-alpha-D-溴代吡喃葡萄糖可用于制备卡格列净。卡格列净Canagliflozin是第一个被FDA批准的SGLT2抑制剂药物，能通过将葡萄糖分解后通过肾脏排出体外的方式来降低血糖，用于治疗成人2型糖尿病，具有广阔的前景。

制备方法

以ALPHA-D-葡萄糖为原料，经与特戊酰氯反应保护所有羟基后，再与溴化锌、三甲基溴硅烷在-10℃反应生成中间体四，上保护基的工艺中加入少量氯化亚砜，使特戊酰氯用量降低一半，收率无影响，两步收率都在82%以上，总收率大于67%。

2,3,4,6-O-四特戊酰基-ALPHA-D-溴代吡喃葡萄糖 上下游产品信息

上游原料

下游产品

2,3,4,6-O-四特戊酰基-ALPHA-D-溴代吡喃葡萄糖 生产厂家

81058-27-7, 2,3,4,6-O-四特戊酰基-ALPHA-D-溴代吡喃葡萄糖 相关搜索:

• Canagliflozin intermediate
• substrate
• SGLT2
• 生化试剂
• 化工中间体-化工原料
• 医药原料
• 医药原料药
• 医药中间体
• C26H43BrO9
• 2,3,4,6-四-O-新戊酰基-Α-D-吡喃葡萄糖基溴化物
• 2.3.4.6-0-四特戊酰基ALPHA-D~溴代吡喳葡萄糖
• 2.3.4.6-0-四特戊酰基ALPHA-D-溴代吡喃萄萄糖
• 2,3,4,5-O-四特戊酰基-ALPHA-D-溴代吡喃葡萄糖
• (2R,3R,4S,5R,6R)-2-溴-6-(((新戊酰氧基)甲基)四氢-2H-吡喃-3,4,5-三基三(2,2-二甲基丙酸酯)(恩格列净杂质)
• 2,3,4,6-四-O-新戊酰基-Α-D-吡喃葡糖基溴化物
• 2,3,4,6-四-氧-特戊酰基-Α-D-溴代吡喃葡萄糖
• 2,3,4,6-O-四特戊酰基-Α-D-溴代吡喃葡萄糖
• 依帕列净杂质35
• (2R,3R,4S,5R,6R)-2-溴-6-((新戊酰氧基)甲基)四氢-2H-吡喃-3,4,5-三基三(2,2-二甲基丙酸酯)
• EMPAGLIFLOZIN杂质35
• 依帕列净杂质66
• 2,3,4,6-四-氧-特戊酰基-Α-D-溴代吡喃葡萄糖
• 2,3,4,6-O-四特戊酰基-ALPHA-D-溴
• 2,3,4,6-O-四特戊酰基-ALPHA-D-溴代吡喃葡萄糖,依帕列净中间体 1KG
• 2,3,4,6-四邻叔戊酰基-ALPHA-D-溴化吡喃葡萄糖
• 2,3,4,6-O-四特戊酰基-ALPHA-D-溴代吡喃葡萄糖,依帕列净中间体
• 2,3,4,6-O-四特戊酰基-ALPHA-D-溴代吡喃葡萄糖
• 卡格列净 中间体 KG-2.1
• 81058-27-7
• 2,3,4,5-O-tetratervaloyl-ALPHA-D-bromopyranoglucose
• (2R,3R,4S,5R,6R)-2-Bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate) (Empagliflozin Impurity）
• 2,3,4,6-TETRA-O-PIVALOYL-ALPHA-D-GLUCOPYRANOSYL
• α-D-Glucopyranosyl bromide, 2,3,4,6-tetrakis(2,2-dimethylpropanoate)
• α-D-glucopyranosyl bromide, 2,3,4,6-tetra-O-pivaloyl
• 2, 3, 4, 6-0-tetrapentanoyl-a-D-Bromopyran glucose
• 2,3,4,6-Tetra-O-Pivaloyl-α-D-Glucopyranosyl Bromide
• 2S,3S,4S,5R,6S)-6-bromo-3,4,5-tris(2,2-dimethylpropanoyloxy)tetrahydropyran-2-yl]methyl 2,2-dimethyl
• [(2S,3S,4S,5R,6S)-6-bromo-3,4,5-tris(2,2-dimethylpropanoylox...
• Tetra-O-pivaloyl-α-D-glucopyranosyl Bromide
• α-D-Glucopyranosyl bromide, 2,3,4,6-tetrakis(2,2-dimethylpropanoate)
• Empagliflozin Impurity 66
• [(2R,3R,4S,5R,6R)-6-bromo-3,4,5-tris[(2,2-dimethylpropanoyl)oxy]oxan-2-yl]methyl 2,2-dimethylpropanoate
• 2,3,4,6-Tetra-O-pivaloyl-α-D-glucopytanosyl bromide
• EOS-61173
• 4. 2,3,4,6-Tetra-O-pivaloyl-alpha-D-glucopyranosyl broMide
• per-O-pivaloyl-±-D-glucopyranosyl bromide
• 2,3,4,6-Tetra-O-pivaloyl-alpha-D-glucopyranosyl bromide (Related Reference)
• 2,3,4,6-Tetra-O-pivaloyl-a-D-glucopytanosyl bromide
• (2R,3R,4S,5R,6R)-2-Bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimet
• 2,3,4,6-Tetra-O-pivaloyl-alpha-D-glucopyranosyl bromide >=90% (TLC)
• α-D-glucopyranosyl bromide, 2,3,4,6-tetra-O-pivaloyl
• Canagliflozin Intermediate3
• (2R,3R,4S,5R,6R)-2-BroMo-6-((pivaloyloxy)Methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-diMethylpropanoate)
• 2,3,4,6-Tetra-O-pivaloyl-a-D-glucopyranosylbromide
• [(2S,3S,4S,5R,6S)-6-broMo-3,4,5-tris(2,2-diMethylpropanoyloxy)tetrahydropyran-2-yl]Methyl2,2-diMethylpropanoate
• 2,3,4,6-Tetra-O-pivaloyl-a-D-glucopyranosyl bromide (stabilised with CaCO3)
• TETRA-O-PIVALOYL-ALPHA-D-GLUCOPYRANOSYL BROMIDE
• TETRAKIS(2,2-DIMETHYLPROPANOATE)-A-D-GLUCOPYRANOSYL BROMIDE